Previous 10 | Next 10 |
Buying Penny Stocks Today? Here’s What You Need to Know Buying penny stocks in 2022 is not for the faint of heart. With so much going on in the stock market, trading penny stocks and blue chips in the last few weeks has been extremely volatile, to say the least. And although ...
Adagio Therapeutics (ADGI) +64% as COVID drug ADG20 meets main goals in trial; EUA filing in Q2. Vyant Bio (VYNT) +29% on FY results. Sonoma Pharmaceuticals (SNOA) +24% launches new urinary tract infection product through distributors in New Zealand, Australia and Sou...
Investors have been impressed at the rapid pace at which the stock market has clawed back its losses from early in 2022. The Nasdaq Composite (NASDAQINDEX: ^IXIC) in particular has rebounded sharply, and so it made sense for the index to take a brief break from its ascent early Wedn...
Adagio Therapeutics (NASDAQ:ADGI) said the main goals were met with statistical significance for all three indications in an ongoing phase 2/3 trial of its intramuscularly administered drug adintrevimab (ADG20) for preventing and treating COVID-19. The company said the pre-and-post-...
Risk of symptomatic COVID-19 was reduced by 71% compared to placebo in pre-exposure prophylaxis and 75% compared to placebo in post-exposure prophylaxis Risk of hospitalization or death in participants with mild to moderate COVID-19 was reduced by 66% compared to placebo in th...
WALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (NASDAQ: ADGI) today announced that it will hold its 2022 Annual Meeting of Stockholders virtually at 8:30 a.m. Eastern Time on May 26, 2022. Additional information regarding the Company’s 2022 Annual Meetin...
Attempts earlier in the pandemic to dose people with polyclonal antibody fractions from recovered patients really didn't work out so well - the efficacy was quite disappointing. And since pretty much everyone was getting infected with Omicron, and the Omicron proteins themselves were ...
Adagio Therapeutics (NASDAQ:ADGI) appointed David Hering as interim CEO, effective immediately. Hering, who will also remain ADGI's COO, succeeds Tillman Gerngross, who resigned as CEO and director. “... we initiated a formal CEO search and plan to appoint an executive with proven expe...
WALTHAM, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced th...
Homology Medicines (NASDAQ:FIXX) -25% on FDA clinical hold for phenylketonuria trial. Karyopharm Therapeutics (NASDAQ:KPTI) -23% as medical chief steps down. Inspirato (NASDAQ:ISPO) -17%. QIWI (NASDAQ:QIWI) -14%. Yandex (NASDAQ:YNDX) -13%. Energy Vault (NYSE:NRGV) -12%. Ar...
News, Short Squeeze, Breakout and More Instantly...
Adagio Therapeutics Inc. Company Name:
ADGI Stock Symbol:
NASDAQ Market:
WALTHAM, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that as part of the annual reconstitution of the Russell stock indexes, Invivyd will be included in ...
Pseudovirus in vitro neutralization data show continued neutralizing activity of VYD222 (pemivibart) against the KP.1.1 FLiRT and KP.3 SARS-CoV-2 variants, virus selections representative of current dominant strains and the most recent FLiRT-containing viruses Invivyd’s new data is...
WALTHAM, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Heal...